Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Tijdschrift voor Kindergeneeskunde
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde 5/2011

01-10-2011

Hersentumoren op kinderleeftijd

Auteurs: Dhr. drs. D. Molanus, Dhr.drs. D.G. van Vuurden, dhr. drs. S.E. Mir, dhr. prof.dr. G.J.L. Kaspers, Dhr. dr. R.J. Vermeulen, Mw. ir. C.M. Korbijn, Dhr. prof.dr. W.P. Vandertop

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 5/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Hersentumoren zijn na leukemie de meest voorkomende vormen van kinderkanker. De frequentste symptomen bij presentatie zijn hoofdpijn, misselijkheid en braken, een abnormaal looppatroon of coördinatiestoornissen, papiloedeem en epileptische insulten. Diagnostiek bestaat uit beeldvorming met MRI-scan en histologische classificatie. De meest voorkomende hersentumoren op de kinderleeftijd zijn astrocytomen – waaronder tractus opticusgliomen en diffuse ponsgliomen –, medulloblastomen, ependymomen en craniofaryngiomen. Afhankelijk van de diagnose bestaat de behandeling uit neurochirurgische resectie, (chemo)radiotherapie en/of chemotherapie. De vijfjaarsoverleving van kinderen met een hersentumor is in de afgelopen decennia verbeterd van 58 naar 74%. Helaas ontstaan in maar liefst 82% van de overlevenden late effecten van ziekte en behandeling. Ontwikkelingen op het gebied van classificatie en nieuwe behandelstrategieën moeten in de toekomst de prognose van deze kinderen verder verbeteren en late effecten verminderen.
vorige artikel Ernstige functionele klachten bij kinderen; een unieke integrale aanpak
volgende artikel Dexamethason in plaats van betamethason bij dreigende vroeggeboorte wegens productiestop: even effectief en veilig?
Literatuur
1.
Centraal Bureau voor de Statistiek. Doodsoorzaken; korte lijst (belangrijke doodsoorzaken), leeftijd, geslacht. 28-5-2009.www.​cbs.​nl. 1-7-2011.
2.
3.
Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS 2009 Statistical Report 2005–2006 (Years of Data Collected).www.​cbtrus.​org. 2011.
4.
5.
Kaatsch P, Steliarova-Foucher E, Crocetti E, et al. Time trends of cancer incidence in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:1961–71.PubMedCrossRef
6.
7.
Wilne S, Collier J, Kennedy C, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007;8:685–95.PubMedCrossRef
8.
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114: 97–109.PubMedCrossRef
9.
Vezina LG. Imaging of central nervous system tumors in children: advances and limitations. J Child Neurol. 2008;23:1128–35.PubMedCrossRef
10.
Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–84.PubMedCrossRef
11.
Schaller BJ, Cornelius JF, Sandu N, Buchfelder M. Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med. 2008;8:711–26.PubMedCrossRef
12.
Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17:503–11.PubMedCrossRef
13.
14.
Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115:5761–70.PubMedCrossRef
15.
Shamji MF, Benoit BG. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus. 2007;23:E3.PubMedCrossRef
16.
Binning MJ, Liu JK, Kestle JRW, et al. Optic pathway gliomas: a review. Neurosurg Focus. 2007;23:E2.PubMedCrossRef
17.
Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. 1995;127:718–22.PubMedCrossRef
18.
Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9:197–206.PubMedCrossRef
19.
Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical – and futuristic – perspective. J Neurooncol. 2005;75:253–66.PubMedCrossRef
20.
Bucci MK, Maity A, Janss AJ, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer. 2004;101:817–24.PubMedCrossRef
21.
Choux M. Brainstem tumors. In: Choux M, ed. Pediatric neurosurgery. New York: Churchill Livingstone, 2000. p. 471–91.
22.
Jansen MH, Schaafsma EJ, Vandertop WP, et al. Diagnostiek, behandeling en beloop van kinderen met diffuse en focale ponstumoren. Ned Tijdschr Oncologie. 2009;6:339–50.
23.
Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241–8.PubMedCrossRef
24.
Jansen MH, Vuurden DG van, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology. Cancer Treat Rev. 2011 Jul 15. [Epub ahead of print]
25.
Robertson PL, Muraszko KM, Brunberg JA, et al. Pediatric midbrain tumors: a benign subgroup of brainstem gliomas. Pediatr Neurosurg. 1995;22:65–73.PubMedCrossRef
26.
Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832–45.PubMed
27.
Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008;70:782–7.PubMedCrossRef
28.
Packer RJ, Gajjar A,Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average- risk medulloblastoma. J Clin Oncol. 2006; 24:4202–8.PubMedCrossRef
29.
Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol. 1999;17:2127–36.PubMed
30.
von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91. Eur J Cancer. 2009;45:1209–17.CrossRef
31.
Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol. 2009;11:201–10.PubMedCrossRef
32.
MacDonald TJ, Rood BR, Santi MR, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist. 2003;8:174–86.PubMedCrossRef
33.
34.
Smyth MD, Horn BN, Russo C, Berger MS. Intracranial ependymomas of childhood: current management strategies. Pediatr Neurosurg. 2000; 33:138–50.PubMedCrossRef
35.
Zacharoulis S, Ji L, Pollack IF, et al. Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors. Pediatr Blood Cancer. 2008;50:231–5.PubMedCrossRef
36.
Agaoglu FY, Ayan I, Dizdar Y, et al. Ependymal tumors in childhood. Pediatr Blood Cancer. 2005;45:298–303.PubMedCrossRef
37.
Nejat F, El Khashab M, Rutka JT. Initial management of childhood brain tumors: neurosurgical considerations. J Child Neurol. 2008;23:1136–48.PubMedCrossRef
38.
Sughrue ME, et al. Craniopharyngioma. In: Gupta N, Banerjee A, Haas-Kogan D, eds. Pediatric CNS tumors. Berlin: Springer, 2010. p. 135–58.CrossRef
39.
Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89:547–51.PubMedCrossRef
40.
Peris-Bonet R, Martinez-Garcia C, Lacour B, et al. Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): report from Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2064–80.PubMedCrossRef
41.
Muller HL. Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up. Horm Res. 2008;69:193–202.PubMedCrossRef
42.
Ohmori K, Collins J, Fukushima T. Craniopharyngiomas in children. Pediatr Neurosurg. 2007;43:265–78.PubMedCrossRef
43.
Suh JH, Gupta N. Role of radiation therapy and radiosurgery in the management of craniopharyngiomas. Neurosurg Clin N Am. 2006;17:143–8.PubMedCrossRef
44.
Crawford JR, Santi MR, Vezina G, et al. CNS germ cell tumor (CNSGCT) of childhood: presentation and delayed diagnosis. Neurology. 2007;68:1668–73.PubMedCrossRef
45.
Al-Hussaini M, Sultan I, Abuirmileh N, et al. Pineal gland tumors: experience from the SEER database. J Neurooncol. 2009;94:351–8.PubMedCrossRef
46.
Baumgartner JE, Sorenson JM. Meningioma in the pediatric population. J Neurooncol. 1996;29:223–8.PubMedCrossRef
47.
48.
Ng WH, Mukhida K, Rutka JT. Image guidance and neuromonitoring in neurosurgery. Childs Nerv Syst. 2010;26:491–502.PubMedCrossRef
49.
Kirsch DG, Tarbell NJ. Conformal radiation therapy for childhood CNS tumors. Oncologist. 2004;9:442–50.PubMedCrossRef
50.
Yock TI, Tarbell NJ. Technology insight: Proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol. 2004;1:97–103.PubMedCrossRef
51.
Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol. 2008;23:1149–59.PubMedCrossRef
52.
Zacharoulis S, Levy A, Chi SN, et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007;49:34–40.PubMedCrossRef
53.
54.
Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:946–58.PubMedCrossRef
55.
Bhat SR, Goodwin TL, Burwinkle TM, et al. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol. 2005;23:5493–500.PubMedCrossRef
56.
Reimers TS, Ehrenfels S, Mortensen EL, et al. Cognitive deficits in long-term survivors of childhood brain tumors: Identification of predictive factors. Med Pediatr Oncol. 2003;40:26–34.PubMedCrossRef
57.
Mulhern RK, Reddick WE, Palmer SL, et al. Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol. 1999;46:834–41.PubMedCrossRef
58.
Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg. 1989;70:707–13.PubMedCrossRef
59.
Beebe DW, Ris MD, Armstrong FD, et al. Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG 9891/POG 9130). J Clin Oncol. 2005;23:5198–204.PubMedCrossRef
60.
Turner CD, Rey-Casserly C, Liptak CC, Chordas C. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol. 2009;24:1455–63.PubMedCrossRef
61.
Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97:663–73.PubMedCrossRef
62.
Pollack IF, Finkelstein SD,Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420–7.PubMedCrossRef
63.
Raffel C, Frederick L, O’Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res. 1999;5:4085–90.PubMed
64.
Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol. 2008;10:675–89.PubMedCrossRef
65.
Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007;6:1073–85.PubMedCrossRef
66.
Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25:1196–208.PubMedCrossRef
67.
Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008;3: 341–65.PubMedCrossRef
68.
Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3:e3088.PubMedCrossRef
69.
Mir SE, De Witt Hamer PC, Krawczyk PM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18:244–57.PubMedCrossRef
Metagegevens
Titel
Hersentumoren op kinderleeftijd
Auteurs
Dhr. drs. D. Molanus
Dhr.drs. D.G. van Vuurden
dhr. drs. S.E. Mir
dhr. prof.dr. G.J.L. Kaspers
Dhr. dr. R.J. Vermeulen
Mw. ir. C.M. Korbijn
Dhr. prof.dr. W.P. Vandertop
Publicatiedatum
01-10-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Kindergeneeskunde / Uitgave 5/2011
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI
https://doi.org/10.1007/s12456-011-0029-4

Andere artikelen Uitgave 5/2011

Tijdschrift voor Kindergeneeskunde 5/2011 Naar de uitgave

Artikelen

Verantwoord voorschrijven van een geneesmiddel; geregistreerd medicijn of conform richtlijn?

OriginalPaper

Dexamethason in plaats van betamethason bij dreigende vroeggeboorte wegens productiestop: even effectief en veilig?

Commentaar

Het voorschrijven van een geneesmiddel: de dagelijkse praktijk

OriginalPaper

Ernstige functionele klachten bij kinderen; een unieke integrale aanpak

OriginalPaper

Wajongers opgegroeid met een somatische aandoening